Inhibition of vascular endothelial growth factor (VEGF)-C/D and vascular endothelial growth factor receptor 3 (VEGFR-3) suggests a lymphatic vessel-targeted immunomodulatory therapy in cardiac allograft rejection and arteriosclerosis model [9]. The gene discussed is FLT4; the disease is arteriosclerosis disorder.